Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.
Patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented. The follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rheumatoid arthritis | Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Disease Activity Score (DAS) 28 | The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Percentage of Participants in DAS28 Remission | Clinical remission is defined as a disease activity score (DAS) 28 score of < 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. | Months 3, 6, 9, 12, 18, and 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With a Significant Therapeutic Response | Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Community sample: patients with rheumatoid arthritis who resided in Germany. German regulations state that all patients are eligible for non-interventional studies; there are no exclusions. Adult patients (≥ 18 years of age) with RA who were preparing to initiate adalimumab therapy according to the product label were eligible for study enrollment. The eligibility criteria below reflect the approved label as stated in the German Summary of Product Characteristics (SPC) for Humira.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bianca Wittig, MD | AbbVie Deutschland GmbH & Co. KG, Medical Department | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site Reference ID/Investigator# 35036 | Aachen | 52062 | Germany | |||
| Site Reference ID/Investigator# 35510 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31311386 | Derived | Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Wittig BM, Gnann H, Greger G, Tony HP, Burkhardt H. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis. Scand J Rheumatol. 2019 Sep;48(5):375-382. doi: 10.1080/03009742.2019.1600717. Epub 2019 Jul 16. | |
| 26990995 |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Rheumatoid Arthritis | Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Percentage of Participants With Low, Moderate and High Disease Activity | The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 >3.2 to ≤5.1; High disease activity as a DAS28 >5.1. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Erythrocyte Sedimentation Rate (ESR) Over Time | Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| C-Reactive Protein (CRP) Levels Over Time | C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Tender Joint Count (TJC) Over Time | Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Swollen Joint Count (SJC) Over Time | Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Hannover Functional Questionnaire (FFbH) Over Time | A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Patients Global Assessment of Disease Activity Over Time | Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Baseline and Months 3, 6, 9, 12, 18 and 24 |
| Participants Assessment of Fatigue Over Time | Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Baseline and Month 3, 6, 9, 12, 18, and 24 |
| Participants Assessment of Pain Over Time | Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Percentage of Participants With Impairment in Daily Activities | Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks. | Baseline and Months 3, 6, 9, 18, and 24 |
| Number of Days Missed From Work Due to Rheumatoid Arthritis | Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months. | Baseline and Months 6, 12, 18, and 24 |
| Percentage of Participants With In-patient Hospitalization | The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months. | Month 6, 12, 18, and 24 |
| Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| Ahlen |
| 59227 |
| Germany |
| Site Reference ID/Investigator# 35040 | Ahrensburg | 22926 | Germany |
| Site Reference ID/Investigator# 35043 | Altenburg | 04600 | Germany |
| Site Reference ID/Investigator# 35046 | Altenholz | 24161 | Germany |
| Site Reference ID/Investigator# 35049 | Amberg | 92224 | Germany |
| Site Reference ID/Investigator# 35057 | Arnstadt | 99310 | Germany |
| Site Reference ID/Investigator# 35520 | Attendorn | 57439 | Germany |
| Site Reference ID/Investigator# 33349 | Augsburg | 86150 | Germany |
| Site Reference ID/Investigator# 33358 | Bad Abbach | 93077 | Germany |
| Site Reference ID/Investigator# 33361 | Bad Abbach | 93077 | Germany |
| Site Reference ID/Investigator# 35142 | Bad Aibling | 83043 | Germany |
| Site Reference ID/Investigator# 35570 | Bad Brambach | 8648 | Germany |
| Site Reference ID/Investigator# 35573 | Bad Bramstedt | 24576 | Germany |
| Site Reference ID/Investigator# 33372 | Bad Endbach | 35080 | Germany |
| Site Reference ID/Investigator# 33378 | Bad Iburg | 49186 | Germany |
| Site Reference ID/Investigator# 33382 | Bad Iburg | 49186 | Germany |
| Site Reference ID/Investigator# 33387 | Bad Kreuznach | 55543 | Germany |
| Site Reference ID/Investigator# 35575 | Bad Kreuznach | 55543 | Germany |
| Site Reference ID/Investigator# 33391 | Bad Liebenwerda | 04924 | Germany |
| Site Reference ID/Investigator# 33396 | Bad Münder am Deister | 31848 | Germany |
| Site Reference ID/Investigator# 102216 | Bad Nauheim | 61231 | Germany |
| Site Reference ID/Investigator# 35578 | Bad Neuenahr | 53474 | Germany |
| Site Reference ID/Investigator# 33404 | Bad Rappenau | 74906 | Germany |
| Site Reference ID/Investigator# 51883 | Bad Salzungen | 36433 | Germany |
| Site Reference ID/Investigator# 33412 | Bad Soden-Salmünster | 63628 | Germany |
| Site Reference ID/Investigator# 33425 | Baden-Baden | 76530 | Germany |
| Site Reference ID/Investigator# 33429 | Bamberg | 96047 | Germany |
| Site Reference ID/Investigator# 33438 | Bautzen | 02625 | Germany |
| Site Reference ID/Investigator# 33442 | Bayreuth | 95445 | Germany |
| Site Reference ID/Investigator# 33446 | Bayreuth | 95445 | Germany |
| Site Reference ID/Investigator# 33641 | Berlin | 10117 | Germany |
| Site Reference ID/Investigator# 35089 | Berlin | 10117 | Germany |
| Site Reference ID/Investigator# 33648 | Berlin | 10178 | Germany |
| Site Reference ID/Investigator# 33693 | Berlin | 10247 | Germany |
| Site Reference ID/Investigator# 33670 | Berlin | 10369 | Germany |
| Site Reference ID/Investigator# 33658 | Berlin | 10435 | Germany |
| Site Reference ID/Investigator# 33697 | Berlin | 10711 | Germany |
| Site Reference ID/Investigator# 34246 | Berlin | 10719 | Germany |
| Site Reference ID/Investigator# 33683 | Berlin | 10777 | Germany |
| Site Reference ID/Investigator# 34269 | Berlin | 10961 | Germany |
| Site Reference ID/Investigator# 35527 | Berlin | 12161 | Germany |
| Site Reference ID/Investigator# 35597 | Berlin | 12161 | Germany |
| Site Reference ID/Investigator# 33620 | Berlin | 12207 | Germany |
| Site Reference ID/Investigator# 33690 | Berlin | 12435 | Germany |
| Site Reference ID/Investigator# 33704 | Berlin | 12435 | Germany |
| Site Reference ID/Investigator# 33687 | Berlin | 13055 | Germany |
| Site Reference ID/Investigator# 33661 | Berlin | 13437 | Germany |
| Site Reference ID/Investigator# 35550 | Berlin | 13595 | Germany |
| Site Reference ID/Investigator# 33674 | Berlin | 14109 | Germany |
| Site Reference ID/Investigator# 35551 | Berlin | 14163 | Germany |
| Site Reference ID/Investigator# 34238 | Berlin | 14199 | Germany |
| Site Reference ID/Investigator# 35556 | Bernau | 16321 | Germany |
| Site Reference ID/Investigator# 34277 | Biberach | 88400 | Germany |
| Site Reference ID/Investigator# 35562 | Binzen | 79589 | Germany |
| Site Reference ID/Investigator# 34285 | Blankenburg/Hart | 38889 | Germany |
| Site Reference ID/Investigator# 34288 | Blaubeuren Abbey | 89143 | Germany |
| Site Reference ID/Investigator# 34291 | Bocholt | 46399 | Germany |
| Site Reference ID/Investigator# 35566 | Bocholt | 46399 | Germany |
| Site Reference ID/Investigator# 35641 | Bochum | 44789 | Germany |
| Site Reference ID/Investigator# 35644 | Bogen | 94327 | Germany |
| Site Reference ID/Investigator# 34302 | Bonn | 53111 | Germany |
| Site Reference ID/Investigator# 35646 | Bonn | 53129 | Germany |
| Site Reference ID/Investigator# 34296 | Bonn | 53177 | Germany |
| Site Reference ID/Investigator# 35652 | Bottrop | 46242 | Germany |
| Site Reference ID/Investigator# 34307 | Braunschweig | 38100 | Germany |
| Site Reference ID/Investigator# 35603 | Breitenbrunn | 08359 | Germany |
| Site Reference ID/Investigator# 35609 | Bremen | 28209 | Germany |
| Site Reference ID/Investigator# 34266 | Buch | 13125 | Germany |
| Site Reference ID/Investigator# 35611 | Celle | 29223 | Germany |
| Site Reference ID/Investigator# 34699 | Chemnitz | 09126 | Germany |
| Site Reference ID/Investigator# 35093 | Chemnitz | D-09130 | Germany |
| Site Reference ID/Investigator# 35615 | Coesfeld | 48653 | Germany |
| Site Reference ID/Investigator# 33989 | Cologne | 50823 | Germany |
| Site Reference ID/Investigator# 35237 | Cologne | 51067 | Germany |
| Site Reference ID/Investigator# 34708 | Cottbus | 03042 | Germany |
| Site Reference ID/Investigator# 34711 | Cottbus | 03046 | Germany |
| Site Reference ID/Investigator# 35621 | Darmstadt | 64295 | Germany |
| Site Reference ID/Investigator# 34725 | Deggendorf | 94469 | Germany |
| Site Reference ID/Investigator# 35631 | Dessau | 6842 | Germany |
| Site Reference ID/Investigator# 34742 | Dortmund | 44147 | Germany |
| Site Reference ID/Investigator# 35635 | Dortmund | 44147 | Germany |
| Site Reference ID/Investigator# 35634 | Dortmund | 44263 | Germany |
| Site Reference ID/Investigator# 35170 | Dresden | 01097 | Germany |
| Site Reference ID/Investigator# 34754 | Dresden | 01109 | Germany |
| Site Reference ID/Investigator# 34748 | Dresden | 01277 | Germany |
| Site Reference ID/Investigator# 34751 | Dresden | 01277 | Germany |
| Site Reference ID/Investigator# 34760 | Dresden | 01277 | Germany |
| Site Reference ID/Investigator# 34778 | Duisburg | 47055 | Germany |
| Site Reference ID/Investigator# 34773 | Düsseldorf | 40211 | Germany |
| Site Reference ID/Investigator# 34768 | Düsseldorf | 40217 | Germany |
| Site Reference ID/Investigator# 34784 | Eberswalde | 16225 | Germany |
| Site Reference ID/Investigator# 35184 | Elmshorn | 25336 | Germany |
| Site Reference ID/Investigator# 34809 | Erfurt | 99096 | Germany |
| Site Reference ID/Investigator# 35096 | Erfurt | 99096 | Germany |
| Site Reference ID/Investigator# 35191 | Erfurt | 99096 | Germany |
| Site Reference ID/Investigator# 34821 | Erlangen | 91056 | Germany |
| Site Reference ID/Investigator# 35196 | Essen | 45326 | Germany |
| Site Reference ID/Investigator# 35199 | Essen | 45356 | Germany |
| Site Reference ID/Investigator# 35202 | Feldafing | 82340 | Germany |
| Site Reference ID/Investigator# 35205 | Flensburg | 24937 | Germany |
| Site Reference ID/Investigator# 34833 | Forchheim | 91301 | Germany |
| Site Reference ID/Investigator# 35210 | Frankenberg | 09669 | Germany |
| Site Reference ID/Investigator# 34849 | Frankfurt | 15230 | Germany |
| Site Reference ID/Investigator# 34840 | Frankfurt | 60596 | Germany |
| Site Reference ID/Investigator# 34843 | Frankfurt | 60596 | Germany |
| Site Reference ID/Investigator# 35213 | Fraureuth | 08427 | Germany |
| Site Reference ID/Investigator# 35219 | Freiberg | 09599 | Germany |
| Site Reference ID/Investigator# 34854 | Freiburg im Breisgau | 79098 | Germany |
| Site Reference ID/Investigator# 35221 | Freiburg im Breisgau | 79104 | Germany |
| Site Reference ID/Investigator# 34861 | Freiburg im Breisgau | 79106 | Germany |
| Site Reference ID/Investigator# 35101 | Freystadt | 92342 | Germany |
| Site Reference ID/Investigator# 35224 | Friedrichroda | 99894 | Germany |
| Site Reference ID/Investigator# 34879 | Gelsenkirchen | 45881 | Germany |
| Site Reference ID/Investigator# 34883 | Gera | 07545 | Germany |
| Site Reference ID/Investigator# 34887 | Giessen | 35392 | Germany |
| Site Reference ID/Investigator# 35491 | Gosheim | 78559 | Germany |
| Site Reference ID/Investigator# 34896 | Goslar | 38642 | Germany |
| Site Reference ID/Investigator# 34901 | Greifswald | 17489 | Germany |
| Site Reference ID/Investigator# 35496 | Greifswald | 17489 | Germany |
| Site Reference ID/Investigator# 34904 | Greifswald | 17491 | Germany |
| Site Reference ID/Investigator# 102217 | Groß Ammensleben | 39326 | Germany |
| Site Reference ID/Investigator# 35498 | Guben | 3172 | Germany |
| Site Reference ID/Investigator# 34912 | Güstrow | 18273 | Germany |
| Site Reference ID/Investigator# 35503 | Hagen | 58089 | Germany |
| Site Reference ID/Investigator# 34937 | Halle | 06108 | Germany |
| Site Reference ID/Investigator# 34940 | Halle | 06108 | Germany |
| Site Reference ID/Investigator# 34922 | Halle | 06112 | Germany |
| Site Reference ID/Investigator# 34944 | Halle | 06120 | Germany |
| Site Reference ID/Investigator# 34932 | Halle | 06128 | Germany |
| Site Reference ID/Investigator# 35444 | Hamburg | 20144 | Germany |
| Site Reference ID/Investigator# 35441 | Hamburg | 20148 | Germany |
| Site Reference ID/Investigator# 34970 | Hamburg | 20251 | Germany |
| Site Reference ID/Investigator# 34952 | Hamburg | 20355 | Germany |
| Site Reference ID/Investigator# 34958 | Hamburg | 21075 | Germany |
| Site Reference ID/Investigator# 35452 | Hamburg | 22081 | Germany |
| Site Reference ID/Investigator# 35007 | Hamburg | 22089 | Germany |
| Site Reference ID/Investigator# 35000 | Hamburg | 22119 | Germany |
| Site Reference ID/Investigator# 34961 | Hamburg | 22147 | Germany |
| Site Reference ID/Investigator# 35449 | Hamburg | 22179 | Germany |
| Site Reference ID/Investigator# 34955 | Hamburg | 22415 | Germany |
| Site Reference ID/Investigator# 34998 | Hamburg | 22459 | Germany |
| Site Reference ID/Investigator# 34994 | Hamburg | 22523 | Germany |
| Site Reference ID/Investigator# 34983 | Hamburg | 22609 | Germany |
| Site Reference ID/Investigator# 34986 | Hamburg | 22609 | Germany |
| Site Reference ID/Investigator# 35111 | Hamburg | 22609 | Germany |
| Site Reference ID/Investigator# 34974 | Hamburg | 22767 | Germany |
| Site Reference ID/Investigator# 35019 | Hanau | 63450 | Germany |
| Site Reference ID/Investigator# 33712 | Hanover | 30159 | Germany |
| Site Reference ID/Investigator# 35025 | Hanover | 30159 | Germany |
| Site Reference ID/Investigator# 34023 | Hansestadt Salzwedel | 29410 | Germany |
| Site Reference ID/Investigator# 33792 | Harrislee | 24955 | Germany |
| Site Reference ID/Investigator# 35459 | Haselünne | 49740 | Germany |
| Site Reference ID/Investigator# 102215 | Heidelberg | 69120 | Germany |
| Site Reference ID/Investigator# 33798 | Heidelberg | 69120 | Germany |
| Site Reference ID/Investigator# 35119 | Heidelberg | 69120 | Germany |
| Site Reference ID/Investigator# 33801 | Heidelberg | 69121 | Germany |
| Site Reference ID/Investigator# 33808 | Heidelberg | 69121 | Germany |
| Site Reference ID/Investigator# 35464 | Heidenheim | 89520 | Germany |
| Site Reference ID/Investigator# 33818 | Heilbad Heiligenstadt | 37308 | Germany |
| Site Reference ID/Investigator# 33825 | Herrsching am Ammersee | 82211 | Germany |
| Site Reference ID/Investigator# 33834 | Hof | 95028 | Germany |
| Site Reference ID/Investigator# 33842 | Hofheim | 65719 | Germany |
| Site Reference ID/Investigator# 33845 | Hohenfelde | 18209 | Germany |
| Site Reference ID/Investigator# 33855 | Illertissen | 89257 | Germany |
| Site Reference ID/Investigator# 33858 | Immenstadt im Allgäu | 87509 | Germany |
| Site Reference ID/Investigator# 35479 | Ingolstadt | 85049 | Germany |
| Site Reference ID/Investigator# 51882 | Jena | 07743 | Germany |
| Site Reference ID/Investigator# 33942 | Jülich | 52428 | Germany |
| Site Reference ID/Investigator# 33946 | Kahla | 07768 | Germany |
| Site Reference ID/Investigator# 35125 | Kahla | 07768 | Germany |
| Site Reference ID/Investigator# 33950 | Kaiserslautern | 67655 | Germany |
| Site Reference ID/Investigator# 33956 | Karlsruhe | 76133 | Germany |
| Site Reference ID/Investigator# 33961 | Karlsruhe | 76133 | Germany |
| Site Reference ID/Investigator# 33964 | Kassel | 34131 | Germany |
| Site Reference ID/Investigator# 34002 | Königs Wusterhausen | 15711 | Germany |
| Site Reference ID/Investigator# 34008 | Kressbronn | 88079 | Germany |
| Site Reference ID/Investigator# 34084 | Kronach | 96317 | Germany |
| Site Reference ID/Investigator# 34005 | Lahr | 77933 | Germany |
| Site Reference ID/Investigator# 35245 | Landau | 76829 | Germany |
| Site Reference ID/Investigator# 34112 | Leipzig | 04109 | Germany |
| Site Reference ID/Investigator# 34106 | Leipzig | 04129 | Germany |
| Site Reference ID/Investigator# 34109 | Leipzig | 04207 | Germany |
| Site Reference ID/Investigator# 34100 | Leipzig | 04299 | Germany |
| Site Reference ID/Investigator# 35254 | Lippstadt | 59555 | Germany |
| Site Reference ID/Investigator# 35306 | Ludwigsfelde | 14974 | Germany |
| Site Reference ID/Investigator# 35262 | Ludwigshafen | 67069 | Germany |
| Site Reference ID/Investigator# 34136 | Lübeck | 23564 | Germany |
| Site Reference ID/Investigator# 34139 | Lüneburg | 21335 | Germany |
| Site Reference ID/Investigator# 34147 | Magdeburg | 39104 | Germany |
| Site Reference ID/Investigator# 34150 | Magdeburg | 39104 | Germany |
| Site Reference ID/Investigator# 35276 | Mainz | 55116 | Germany |
| Site Reference ID/Investigator# 34192 | Marktredwitz | 95615 | Germany |
| Site Reference ID/Investigator# 34196 | Marl | 45768 | Germany |
| Site Reference ID/Investigator# 34200 | Meissen | 01662 | Germany |
| Site Reference ID/Investigator# 35285 | Menz | 39175 | Germany |
| Site Reference ID/Investigator# 35287 | Minden | 32429 | Germany |
| Site Reference ID/Investigator# 34208 | Mittelherwigsdorf | 02763 | Germany |
| Site Reference ID/Investigator# 34221 | Moenkeberg | 24248 | Germany |
| Site Reference ID/Investigator# 34218 | Mönchengladbach | 41061 | Germany |
| Site Reference ID/Investigator# 34213 | Mönchengladbach | 41199 | Germany |
| Site Reference ID/Investigator# 34040 | Munich | 80639 | Germany |
| Site Reference ID/Investigator# 35295 | Munich | 81377 | Germany |
| Site Reference ID/Investigator# 34232 | Munich | 81547 | Germany |
| Site Reference ID/Investigator# 34235 | Munich | 81547 | Germany |
| Site Reference ID/Investigator# 35298 | Munich | 81667 | Germany |
| Site Reference ID/Investigator# 34043 | Munich | 81925 | Germany |
| Site Reference ID/Investigator# 34224 | Mühlhausen | 99974 | Germany |
| Site Reference ID/Investigator# 35292 | Mülheim | 45468 | Germany |
| Site Reference ID/Investigator# 34229 | Müllheim | 79379 | Germany |
| Site Reference ID/Investigator# 34048 | Münster | 48149 | Germany |
| Site Reference ID/Investigator# 34052 | Naunhof | 04683 | Germany |
| Site Reference ID/Investigator# 34061 | Neubrandenburg | 17033 | Germany |
| Site Reference ID/Investigator# 34064 | Neuburg am Inn | 86633 | Germany |
| Site Reference ID/Investigator# 34071 | Neumünster | 24534 | Germany |
| Site Reference ID/Investigator# 35313 | Neuss | 41460 | Germany |
| Site Reference ID/Investigator# 34076 | Neustadt | 67434 | Germany |
| Site Reference ID/Investigator# 35321 | Niederbrombach | 55767 | Germany |
| Site Reference ID/Investigator# 34080 | Niefern-Öschelbronn | 75223 | Germany |
| Site Reference ID/Investigator# 34158 | Nienburg | 31582 | Germany |
| Site Reference ID/Investigator# 34173 | Oelsnitz | 09376 | Germany |
| Site Reference ID/Investigator# 34176 | Offenburg | 77652 | Germany |
| Site Reference ID/Investigator# 33492 | Oldenburg | 26121 | Germany |
| Site Reference ID/Investigator# 34718 | Ostseebad Damp | 24351 | Germany |
| Site Reference ID/Investigator# 35335 | Paderborn | 33098 | Germany |
| Site Reference ID/Investigator# 33508 | Parchim | 19370 | Germany |
| Site Reference ID/Investigator# 35340 | Passau | 94032 | Germany |
| Site Reference ID/Investigator# 33517 | Pfullendorf | 88630 | Germany |
| Site Reference ID/Investigator# 67482 | Pirna | 01796 | Germany |
| Site Reference ID/Investigator# 33523 | Planegg | 82152 | Germany |
| Site Reference ID/Investigator# 33528 | Plauen | 08523 | Germany |
| Site Reference ID/Investigator# 33470 | Potsdam | 14467 | Germany |
| Site Reference ID/Investigator# 33466 | Potsdam | 14469 | Germany |
| Site Reference ID/Investigator# 33476 | Prüm | 54595 | Germany |
| Site Reference ID/Investigator# 33479 | Püttlingen | 66346 | Germany |
| Site Reference ID/Investigator# 33484 | Radebeul | 01445 | Germany |
| Site Reference ID/Investigator# 35347 | Radebeul | 01445 | Germany |
| Site Reference ID/Investigator# 35136 | Ratingen | 40882 | Germany |
| Site Reference ID/Investigator# 33488 | Ratzeburg | 23909 | Germany |
| Site Reference ID/Investigator# 33890 | Regensburg | 93049 | Germany |
| Site Reference ID/Investigator# 33883 | Regensburg | 93051 | Germany |
| Site Reference ID/Investigator# 33886 | Regensburg | 93051 | Germany |
| Site Reference ID/Investigator# 33897 | Reken | 48734 | Germany |
| Site Reference ID/Investigator# 33902 | Rendsburg | 24768 | Germany |
| Site Reference ID/Investigator# 33907 | Rheine | 48431 | Germany |
| Site Reference ID/Investigator# 35355 | Rickenbach | 79736 | Germany |
| Site Reference ID/Investigator# 33911 | Riesa | 01589 | Germany |
| Site Reference ID/Investigator# 33914 | Rinteln | 31737 | Germany |
| Site Reference ID/Investigator# 33923 | Rostock | 18059 | Germany |
| Site Reference ID/Investigator# 33927 | Rostock | 18059 | Germany |
| Site Reference ID/Investigator# 33931 | Rothenburg | 02929 | Germany |
| Site Reference ID/Investigator# 35362 | Rüdersdorf | 15562 | Germany |
| Site Reference ID/Investigator# 34016 | Saarbrücken | 66111 | Germany |
| Site Reference ID/Investigator# 35383 | Saint Martin | 67487 | Germany |
| Site Reference ID/Investigator# 34027 | Sande | 26452 | Germany |
| Site Reference ID/Investigator# 33534 | Schneeberg | 08289 | Germany |
| Site Reference ID/Investigator# 33539 | Schramberg | 78713 | Germany |
| Site Reference ID/Investigator# 33542 | Schutterwald | 77746 | Germany |
| Site Reference ID/Investigator# 35371 | Schwandorf in Bayern | 92421 | Germany |
| Site Reference ID/Investigator# 33549 | Schwerin | 19053 | Germany |
| Site Reference ID/Investigator# 35376 | Schwerin | 19053 | Germany |
| Site Reference ID/Investigator# 33555 | Schwerte | 58239 | Germany |
| Site Reference ID/Investigator# 33559 | Seesen | 38723 | Germany |
| Site Reference ID/Investigator# 33563 | Senden | 48308 | Germany |
| Site Reference ID/Investigator# 35380 | Singen | 78224 | Germany |
| Site Reference ID/Investigator# 33567 | Sinsheim | 74889 | Germany |
| Site Reference ID/Investigator# 33572 | Soltau | 29614 | Germany |
| Site Reference ID/Investigator# 33577 | Spremberg | 03130 | Germany |
| Site Reference ID/Investigator# 33588 | Stadthagen | 31655 | Germany |
| Site Reference ID/Investigator# 33592 | Steinhagen | 33803 | Germany |
| Site Reference ID/Investigator# 33604 | Stuttgart | 70178 | Germany |
| Site Reference ID/Investigator# 33607 | Stuttgart | 70178 | Germany |
| Site Reference ID/Investigator# 33611 | Stuttgart | 70199 | Germany |
| Site Reference ID/Investigator# 33598 | Stuttgart | 70372 | Germany |
| Site Reference ID/Investigator# 35389 | Suhl | 98529 | Germany |
| Site Reference ID/Investigator# 35391 | Tegernau | 79692 | Germany |
| Site Reference ID/Investigator# 33625 | Torgelow | 17358 | Germany |
| Site Reference ID/Investigator# 33637 | Ueberlingen-Nussdorf | 88662 | Germany |
| Site Reference ID/Investigator# 35395 | Uffenheim | 97215 | Germany |
| Site Reference ID/Investigator# 33721 | Ulm | 89073 | Germany |
| Site Reference ID/Investigator# 33724 | Ulm | 89073 | Germany |
| Site Reference ID/Investigator# 33734 | Viersen | 41747 | Germany |
| Site Reference ID/Investigator# 33737 | Villingen-Schwenningen | 78054 | Germany |
| Site Reference ID/Investigator# 35397 | Vöhringen | 72189 | Germany |
| Site Reference ID/Investigator# 33742 | Waltrop | 45731 | Germany |
| Site Reference ID/Investigator# 34252 | Wannsee | 14109 | Germany |
| Site Reference ID/Investigator# 33749 | Weener | 26826 | Germany |
| Site Reference ID/Investigator# 33751 | Weißenfels | 06667 | Germany |
| Site Reference ID/Investigator# 33852 | Welzow | 03119 | Germany |
| Site Reference ID/Investigator# 35404 | Wiefelstede | 26215 | Germany |
| Site Reference ID/Investigator# 33761 | Wiesbaden | 65189 | Germany |
| Site Reference ID/Investigator# 35408 | Wiesbaden | 65189 | Germany |
| Site Reference ID/Investigator# 33765 | Wiesbaden | 65191 | Germany |
| Site Reference ID/Investigator# 35413 | Wiesbaden | 65191 | Germany |
| Site Reference ID/Investigator# 33772 | Wilhelmshaven | 26382 | Germany |
| Site Reference ID/Investigator# 33780 | Wittlich | 54516 | Germany |
| Site Reference ID/Investigator# 35420 | Wuppertal | 42105 | Germany |
| Site Reference ID/Investigator# 33718 | Würzburg | 97070 | Germany |
| Site Reference ID/Investigator# 33864 | Zerbst | 39261 | Germany |
| Site Reference ID/Investigator# 33867 | Zeven | 27404 | Germany |
| Site Reference ID/Investigator# 33873 | Zwickau | 08056 | Germany |
| Site Reference ID/Investigator# 33876 | Zwickau | 08060 | Germany |
| Site Reference ID/Investigator# 33880 | Zwiesel | 94227 | Germany |
| Scharbatke EC, Behrens F, Schmalzing M, Koehm M, Greger G, Gnann H, Burkhardt H, Tony HP. Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1607-1615. doi: 10.1002/acr.22884. Epub 2016 Oct 1. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Rheumatoid Arthritis | Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Age data was available for 4147 participants | Mean | Standard Deviation | years |
| |||||||||||||||||||||
| Gender | Gender data available for 4157 participants | Number | participants |
| ||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Disease Activity Score (DAS) 28 | The Disease Activity Score 28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28 score. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission. | Full analysis set (FAS). Participants with inadequate data or who met other exclusion criteria were not included in the FAS. "n" indicates the number of participants with available data at each time point. | Posted | Mean | Standard Deviation | units on a scale | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
|
| |||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants in DAS28 Remission | Clinical remission is defined as a disease activity score (DAS) 28 score of < 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. | Full analysis set with available data at each time point (indicated by n) | Posted | Number | percentage of participants | Months 3, 6, 9, 12, 18, and 24 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With a Significant Therapeutic Response | Significant therapeutic response was determined by DAS28 critical difference (Dcrit). A Dcrit response is a statistically determined value that exceeds the threshold of random fluctuation and signifies a positive individual response during treatment. A DAS28-Dcrit individual therapeutic response is defined as a decrease (improvement) in DAS28 from Baseline of ≥ 1.8. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. | Full analysis set with available data at each time point (indicated by n) | Posted | Number | percentage of participants | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Low, Moderate and High Disease Activity | The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity (assessed on a visual analog scale [VAS] from 0 to 10 cm) are included in the DAS28. If the ESR value is missing, the C-reactive protein (CRP) value can be substituted. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Low disease activity is defined as a DAS28 score ≤ 3.2; Moderate disease activity as a DAS28 >3.2 to ≤5.1; High disease activity as a DAS28 >5.1. | Full analysis set with available data at each time point | Posted | Number | percentage of participants | Baseline and Months 3, 6, 9, 12, 18, and 24 |
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Erythrocyte Sedimentation Rate (ESR) Over Time | Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | mm/hour | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | C-Reactive Protein (CRP) Levels Over Time | C-Reactive Protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | mg/L | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Tender Joint Count (TJC) Over Time | Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | tender joints | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Swollen Joint Count (SJC) Over Time | Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | swollen joints | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Hannover Functional Questionnaire (FFbH) Over Time | A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score. The FFbH was calculated from this patient score by the following formula: FFbH = (patient score x 100) ÷ 2 (number of valid responses). The resulting FFbH score reflects the degree of remaining functional capacity where 0 indicates maximal impairment and 100 indicates maximal functional capacity. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | units on a scale | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Patients Global Assessment of Disease Activity Over Time | Participants indicated their global assessment of disease activity over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | cm | Baseline and Months 3, 6, 9, 12, 18 and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Participants Assessment of Fatigue Over Time | Participants indicated their level of fatigue over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | cm | Baseline and Month 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Participants Assessment of Pain Over Time | Participants indicated their level of pain over the last 7 days on a visual analog scale (VAS) from 0 (best) to 10 (worst) cm; lower scores indicate better patient status. | Full analysis set with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | cm | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Impairment in Daily Activities | Participants were asked to report how many days of impairment in daily activities they had experienced in the last 4 weeks. | Full analysis set with available data at each time point | Posted | Number | percentage of participants | Baseline and Months 3, 6, 9, 18, and 24 |
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Days Missed From Work Due to Rheumatoid Arthritis | Participants reported the number of days they had missed from work in the prior 6 months. The Baseline measurement includes data for the prior 12 months. | Full analysis set participants who were employed and with available data at each time point (indicated by n) | Posted | Mean | Standard Deviation | days | Baseline and Months 6, 12, 18, and 24 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With In-patient Hospitalization | The percentage of participants with in-patient hospitalization in the prior 6 months. Baseline data includes in-patient hospitalizations that occurred within the prior 12 months. | Full analysis set with available data at each time point (indicated by n) | Posted | Number | percentage of participants | Month 6, 12, 18, and 24 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication | Full analysis set with available data at each time point (indicated by n) | Posted | Number | percentage of participants | Baseline and Months 3, 6, 9, 12, 18, and 24 |
|
Adverse events (AEs) were collected throughout the 24-month period.
During this non-interventional study, clinicians were asked to report AEs considered to be related to the study medication for all patients who received at least one dose of adalimumab (safety set; N = 4208).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Rheumatoid Arthritis | Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months. | 245 | 4,208 | 0 | 4,208 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Herpes zoster | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Oral herpes | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Bronchopneumonia | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Laryngitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Rash pustular | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Gastrointestinal infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Localized infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Respiratory tract infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Tonsillitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Abscess limb | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Acute tonsillitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Chronic sinusitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Device-related infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Encephalitis viral | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Fungal infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Furuncle | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Genital herpes | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Herpes simplex | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Herpes virus infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Infection susceptibility increased | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Mastoiditis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Otitis media | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Pneumocystis jiroveci pneumonia | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Pneumonia staphylococcal | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Pyelonephritis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Pyothorax | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Sinobronchitis | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Skin infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Staphylococcal infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Tooth abscess | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Vulvovaginal mycotic infection | Infections and infestations | MedDRA v12.1 | Systematic Assessment |
| |
| Infection site erythema | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site pruritus | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Unevaluable event | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site pain | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Edema | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Inflammation | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site swelling | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site urticaria | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Adverse drug reaction | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Chills | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Condition aggravated | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Death | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Disease recurrence | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site induration | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Injection site scab | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Local swelling | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Malaise | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Mucosal dryness | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Obstruction | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Peripheral edema | General disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Dermatitis allergic | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Eczema | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pruritus generalized | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Rash pruritic | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Nail discoloration | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pustular psoriasis | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Skin reaction | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Acne | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cutaneous vasculitis | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Dermatitis acneiform | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Lichenoid keratosis | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Rash generalized | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Skin discomfort | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Skin nodule | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Swelling face | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Alveolitis | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Alveolitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Dry throat | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hypercapnia | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pleurisy | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Throat irritation | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Upper airway obstruction | Respiratory, thoracic and mediastinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Abdominal discomfort | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Abdominal pain lower | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Acute abdomen | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Aphthous stomatitis | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Gastric ulcer | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Gastroesophageal reflux disease | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Glossodynia | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hematochezia | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hypoesthesia oral | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Mouth ulceration | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Mouth edema | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Oral pain | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pancreatitis acute | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Swollen tongue | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Tongue blistering | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Tongue disorder | Gastrointestinal disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hospitalization | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Joint arthroplasty | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Synovectomy | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Injection | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Surgery | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Antibiotic therapy | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Arthrodesis | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Esophageal operation | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Mastoid operation | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Mastoidectomy | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Rehabilitation therapy | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Sinus operation | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Spinal operation | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Stent placement | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Therapy cessation | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Vertebroplasty | Surgical and medical procedures | MedDRA v12.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cerebrovascular accident | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Anosmia | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Aphasia | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Carotid artery stenosis | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hemiparesis | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hypogeusia | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Neuralgia | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Neurological symptom | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Polyneuropathy | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Transient ischemic attack | Nervous system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Congestive cardiomyopathy | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Atrial tachycardia | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pericardial effusion | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pericarditis | Cardiac disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Foot fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Bloody airway discharge | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Femur fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Limb injury | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Spinal fracture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Tendon rupture | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Wound secretion | Injury, poisoning and procedural complications | MedDRA v12.1 | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Joint effusion | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Fasciitis | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Lupus-like syndrome | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Osteonecrosis | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Osteoporosis | Musculoskeletal and connective tissue disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Skin cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Skin papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Large intestine cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Laryngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Metastases to liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Papillary tumor of renal pelvis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Urteric cancer local | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v12.1 | Systematic Assessment |
| |
| Eyelid edema | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Eyelid exfoliation | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Eyelids pruritus | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Visual acuity reduced | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Xerophthalmia | Eye disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Arthroscopy | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Antinuclar antibody positive | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Arteriogram coronary | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| DNA antibody positive | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Electrophoresis protein abnormal | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Hepatic enzyme increased | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Transaminase increased | Investigations | MedDRA v12.1 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Restlessness | Psychiatric disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Panic reaction | Psychiatric disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Sleep disorder | Psychiatric disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Bladder tamponade | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Chromaturia | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Cystitis hemorrhagic | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Micturition urgency | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Nephritis | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Flushing | Vascular disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Venous thrombosis | Vascular disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Venous thrombosis limb | Vascular disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Anemia hemolytic autoimmune | Blood and lymphatic system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Leukopenia | Blood and lymphatic system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Pancytopenia | Blood and lymphatic system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Erectile dysfunction | Reproductive system and breast disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Uterine prolapse | Reproductive system and breast disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hepatotoxicity | Hepatobiliary disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA v12.1 | Systematic Assessment |
| |
| Electrolyte imbalance | Metabolism and nutrition disorders | MedDRA v12.1 | Systematic Assessment |
|
Not provided
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | AbbVie (prior sponsor, Abbott) | 800-633-9110 |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| Month 12 (n=1776) |
|
| Month 18 (n=1519) |
|
| Month 24 (n=1248) |
|
|
|
9 months after inclusion |
| OG004 | Month 12 | 12 months after inclusion |
| OG005 | Month 18 | 18 months after inclusion |
| OG006 | Month 24 | 24 months after inclusion |
|
|
|
|
|
|
|
|
|
|
| Month 24 |
24 months after inclusion |
|
|
|
|
18 months after inclusion
| OG006 | Month 24 | 24 months after inclusion |
|
|